Cost analyses of remifentanil, mivacurium and ropivacaine - a systematic review.
Remifentanil, mivacurium and ropivacaine are the latest innovations in clinical anaesthesia and have gained increasing importance in daily practise due to their unique pharmacodynamic and pharmacokinetic properties. However, drug acquisition costs for these agents are considerably higher in most countries than for comparable substances. This review provides a systematic, critical appraisal of pharmacoeconomic studies with remifentanil, mivacurium and ropivacaine, primarily based on prospective, randomised trials. Results from analyses using cost-minimising techniques stress the issue of the higher drug acquisition costs. However, studies using a more sophisticated method (e.g., cost-effectiveness analysis) indicate comparable costs or even financial advantage in favour of the newer investigative drugs remifentanil, mivacurium and ropivacaine.
Department of Anaesthesia and Intensive Care Medicine, Philipps-University, Marburg, Germany.
Timon
T
Vassiliou
Caroline
C
Putzke
Götz
G
Geldner
Leopold
L
Eberhart
D000577:Amides / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005858:Germany; D006801:Humans; D007546:Isoquinolines / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D000077590:Mivacurium; D010880:Piperidines / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000191:economics; D000077208:Remifentanil; D000077212:Ropivacaine
D000577:Amides; D007546:Isoquinolines; D010880:Piperidines; D000077590:Mivacurium; D000077212:Ropivacaine; D000077208:Remifentanil